Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Rifabutin Prophylaxis for MAC Infection

Rifabutin Prophylaxis for MAC Infection Drug Profile Rifabutin MAC Infection By Maxine Karpen, R.N. for the Prophylaxis for in Canada. The double-blind phase was completed in January 1992 and the trans¬ fer over to labeled drug was completed one month later. In both studies, the mean age of the total patient population was about 38 years, the predominate sex was male, the predominate race Caucasian, and the pre¬ dominate antiretroviral therapy was zidovudine. All of the patients in the study were at high risk for developing disseminated MAC infection. The trials evidenced no significant dif¬ ference in survival between the placebo group and the rifabutin group. According to Dr. Nightingale, the principal causes of death in both groups were CMV infection and Kaposi's sarcoma. There was, howev¬ er, a significant difference in the develop¬ ment of fever and fatigue observed between the two groups, in favor of rifabutin, with severe incidences of these symptoms appearing sooner in the place¬ bo group—some six months sooner, according to Dr. Nightingale. "And that is a conservative answer," he states, "since we are still waiting for some patients to Editor's Note: As this issue goes to press, the FDA antiviral drug advisory commit¬ tee recommended that rifabutin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Rifabutin Prophylaxis for MAC Infection

AIDS Patient Care , Volume 6 (6) – Dec 1, 1992

Rifabutin Prophylaxis for MAC Infection

AIDS Patient Care , Volume 6 (6) – Dec 1, 1992

Abstract

Drug Profile Rifabutin MAC Infection By Maxine Karpen, R.N. for the Prophylaxis for in Canada. The double-blind phase was completed in January 1992 and the trans¬ fer over to labeled drug was completed one month later. In both studies, the mean age of the total patient population was about 38 years, the predominate sex was male, the predominate race Caucasian, and the pre¬ dominate antiretroviral therapy was zidovudine. All of the patients in the study were at high risk for developing disseminated MAC infection. The trials evidenced no significant dif¬ ference in survival between the placebo group and the rifabutin group. According to Dr. Nightingale, the principal causes of death in both groups were CMV infection and Kaposi's sarcoma. There was, howev¬ er, a significant difference in the develop¬ ment of fever and fatigue observed between the two groups, in favor of rifabutin, with severe incidences of these symptoms appearing sooner in the place¬ bo group—some six months sooner, according to Dr. Nightingale. "And that is a conservative answer," he states, "since we are still waiting for some patients to Editor's Note: As this issue goes to press, the FDA antiviral drug advisory commit¬ tee recommended that rifabutin

Loading next page...
 
/lp/mary-ann-liebert/rifabutin-prophylaxis-for-mac-infection-3GtkbCXc1C
Publisher
Mary Ann Liebert
Copyright
Copyright 1992 Mary Ann Liebert, Inc.
Subject
Drug Profile
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1992.6.276
Publisher site
See Article on Publisher Site

Abstract

Drug Profile Rifabutin MAC Infection By Maxine Karpen, R.N. for the Prophylaxis for in Canada. The double-blind phase was completed in January 1992 and the trans¬ fer over to labeled drug was completed one month later. In both studies, the mean age of the total patient population was about 38 years, the predominate sex was male, the predominate race Caucasian, and the pre¬ dominate antiretroviral therapy was zidovudine. All of the patients in the study were at high risk for developing disseminated MAC infection. The trials evidenced no significant dif¬ ference in survival between the placebo group and the rifabutin group. According to Dr. Nightingale, the principal causes of death in both groups were CMV infection and Kaposi's sarcoma. There was, howev¬ er, a significant difference in the develop¬ ment of fever and fatigue observed between the two groups, in favor of rifabutin, with severe incidences of these symptoms appearing sooner in the place¬ bo group—some six months sooner, according to Dr. Nightingale. "And that is a conservative answer," he states, "since we are still waiting for some patients to Editor's Note: As this issue goes to press, the FDA antiviral drug advisory commit¬ tee recommended that rifabutin

Journal

AIDS Patient CareMary Ann Liebert

Published: Dec 1, 1992

There are no references for this article.